For Q1 FY2026 ended March 31, 2026, Damora Therapeutics reported a net loss of $27.8 million, a significant increase from the prior year. Operating loss was $30.8 million, and diluted EPS was -$0.62. The company held $532.9 million in cash and $511.6 million in equity.
•Net loss of $27.8 million, up 997% year-over-year.
•Operating loss of $30.8 million, up 1,085% year-over-year.
•Diluted EPS of -$0.62, improved 68% year-over-year.
•Cash and cash equivalents of $532.9 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Damora Therapeutics, Inc., a biopharmaceutical company develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Founded in 2011, Damora Therapeutics is headquartered in Waltham, Massachusetts.
Damora Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for hematologic disorders, primarily in Denmark and North America. Its lead product candidate is DMR-001, an investigational monoclonal antibody therapy targeting mutations in CALR, designed to treat essential thrombocythemia. The company also has DMR-002 and DMR-003, both anti-mutCALR-based therapies aimed at addressing the full spectrum of mutCALR myeloproliferative neoplasm (MPN) patients. Additionally, Damora is developing GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. These programs target specific genetic mutations and pathways involved in blood cancers.
Where is Damora Therapeutics (DMRA) listed and what currency is used?
Damora Therapeutics, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol DMRA. The company's stock is traded in U.S. dollars (USD), reflecting its primary listing in the United States. As a U.S.-based biopharmaceutical company with operations in Denmark and North America, its financial reporting and trading currency are in USD.
What sector and industry does Damora Therapeutics (DMRA) operate in?
Damora Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on researching and developing innovative therapies for hematologic disorders, including blood cancers such as essential thrombocythemia and acute myeloid leukemia. The biotechnology industry involves using biological processes and genetic engineering to create treatments, and Damora's pipeline includes monoclonal antibodies and small molecule inhibitors targeting specific genetic mutations.
Where is Damora Therapeutics headquartered and what markets does it serve?
Damora Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States. The company was founded in 2011 and develops therapies for hematologic disorders in Denmark and North America. Its operations span both the U.S. and Denmark, indicating a transatlantic focus for research and development activities. The primary markets served include the United States and Canada (North America) as well as Denmark, with potential expansion to other regions as its product candidates advance.
What are the main product candidates in Damora Therapeutics' (DMRA) pipeline?
Damora Therapeutics' pipeline includes several product candidates targeting hematologic malignancies. The lead candidate is DMR-001, an investigational monoclonal antibody therapy that targets mutations in CALR, intended for the treatment of essential thrombocythemia. The company is also developing DMR-002 and DMR-003, both anti-mutCALR-based therapies designed to address the full spectrum of mutCALR myeloproliferative neoplasm (MPN) patients. Additionally, Damora has GB3226, a small molecule inhibitor of ENL-YEATS and FLT3, for the treatment of acute myeloid leukemia. These candidates are in various stages of development, focusing on genetically defined subsets of blood cancers.